Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon DiseaseBusiness Wire • 12/08/20
Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/06/20
Rocket Pharmaceuticals to Hold Webcast for Investors Highlighting Data Presented at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/02/20
Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant OsteopetrosisBusiness Wire • 11/13/20
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 11/04/20
Rocket Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 11/04/20
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/16/20
Rocket Pharmaceuticals Announces Two Presentations at the European Society for Immunodeficiencies 2020 MeetingBusiness Wire • 10/01/20
Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon DiseaseBusiness Wire • 09/02/20
Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 08/27/20
Rocket Pharmaceuticals Expands Clinical Sites for its FA, Danon, LAD-I and IMO Trials, Adding to its Global Centers of ExcellenceBusiness Wire • 08/26/20
Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent ProgressBusiness Wire • 08/05/20
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase DeficiencyBusiness Wire • 07/13/20
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 06/29/20
Rocket Pharmaceuticals: Updating Our Bullish View For Recent Events - Still A BUYSeeking Alpha • 05/27/20
Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to BuyZacks Investment Research • 01/06/20
Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue?Zacks Investment Research • 12/04/19